SCHEMBL10123733

SCHEMBL10123733

CCN(c1cccc(C(F)(F)F)c1)c1ccccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTC4S Q16873 2/20 0.47
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
GAA P10253 2/20 0.45
GRIK1 P39086 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
TAS2R14 Q9NYV8 1/20 0.41
NOTUM Q6P988 1/20 0.41
RORC P51449 2/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
RORB Q92753 1/20 0.40
POLQ O75417 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10598192 0.88 GAA (0.44) LTC4SMEN1KMT2AGAAGRIK1
SCHEMBL14399046 0.88 MEN1 (0.43) LTC4SMEN1KMT2AGAAGRIK1
SCHEMBL11135315 0.86 MEN1 (0.53) LTC4SMEN1KMT2AGAAGRIK1
SCHEMBL10946240 0.84 GRIK1 (0.47) MEN1KMT2AGAAGRIK1RXFP1
SCHEMBL11347335 0.83 RXFP1 (0.47) MEN1KMT2AGAAGRIK1RXFP1
SCHEMBL10123771 0.81 KMT2A (0.50) LTC4SMEN1KMT2AGAARXFP1
SCHEMBL10108680 0.81 TAS2R14 (0.45) MEN1KMT2AGAAGRIK1RXFP1
SCHEMBL3500553 0.80 LMNA (0.46) LTC4SMEN1KMT2AGAAGRIK1
SCHEMBL10599602 0.80 MEN1 (0.45) MEN1KMT2AGAAGRIK1RXFP1
SCHEMBL7062441 0.78 PTPN1 (0.54) MEN1KMT2AGAAGRIK1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0130524-B1 DEPOT ANTIPHLOGISTICS Troponwerke GmbH & Co. KG (DE) 1989-08-23 EP claimed
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261950-A1 Compounds that inhibit cholinesterase ACHE, BCHE, CHAT LTC4S 324/4885MEN1 1391/4885KMT2A 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.